UNIVERSITY OF ZAMBIA
πΏπ²Zambia
- Country
- πΏπ²Zambia
- Ownership
- Private
- Established
- 1966-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.unza.zm
Clinical Trials
5
Active:0
Completed:4
Trial Phases
4 Phases
Phase 1:1
Phase 3:1
Phase 4:1
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)β’ Click on a phase to view related trials
Not Applicable
1 (25.0%)Phase 1
1 (25.0%)Phase 3
1 (25.0%)Phase 4
1 (25.0%)Glycaemic & Cardiovascular Treatment Outcomes of Voglibose Vs Glibenclamide Added to Metformin in T2DM Patients
Phase 3
Not yet recruiting
- Conditions
- Diabetes Mellitus Type 2 Without Complication
- Interventions
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- University of Zambia
- Target Recruit Count
- 118
- Registration Number
- NCT05688332
Rheumatic Heart Disease Study in Lusaka
Completed
- Conditions
- Rheumatic Heart Disease
- First Posted Date
- 2016-01-22
- Last Posted Date
- 2016-11-08
- Lead Sponsor
- University of Zambia
- Target Recruit Count
- 1024
- Registration Number
- NCT02661763
- Locations
- πΏπ²
University Teaching Hosptial, Lusaka, Zambia
Targeting Interventions at Venues Where Risk of HIV Transmission is High
Phase 1
Completed
- Conditions
- HIV
- First Posted Date
- 2011-08-25
- Last Posted Date
- 2011-08-25
- Lead Sponsor
- University of Zambia
- Target Recruit Count
- 537
- Registration Number
- NCT01423357
- Locations
- πΏπ²
Dambwa, Livingstone, Zambia
πΏπ²Maramba, Livingstone, Zambia
Taenia Solium Control Case Study in Zambia
Not Applicable
Completed
- Conditions
- CysticercosisHelminthiasis
- First Posted Date
- 2011-06-07
- Last Posted Date
- 2015-02-11
- Lead Sponsor
- University of Zambia
- Target Recruit Count
- 1197
- Registration Number
- NCT01368354
- Locations
- πΏπ²
Katete, Katete district, Eastern, Zambia
Clinical Study of an Aluvia-based HAART Regimen for Prevention of Mother-to-child HIV Transmission in Africa
Phase 4
Completed
- Conditions
- HIV
- Interventions
- Drug: Lopinavir/Ritonavir (200/50 mg) Tablets + Zidovudine + 3TC
- First Posted Date
- 2010-03-17
- Last Posted Date
- 2015-06-24
- Lead Sponsor
- University of Zambia
- Target Recruit Count
- 280
- Registration Number
- NCT01088516
- Locations
- πΏπ²
Chelstone Clinic, Lusaka, Zambia
News
No news found